カテゴリ： GlobalData, カナダ, 企業調査

Valeant Pharmaceuticals International Inc (VRX)-医療機器分野：企業M&A・提携分析

◆英語タイトル：Valeant Pharmaceuticals International Inc (VRX) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA8011962
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月14日
◆ページ数：157
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：カナダ
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Valeant Pharmaceuticals International Inc (Valeant) is a pharmaceutical and medical device company that carries out development, manufacture and marketing of several branded, over-the-counter (OTC) and generic drugs. The company also offers medical devices such as medical contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices. Valeant offers products in the areas of dermatology, neurology, eye health and branded generics. It offers a diverse mix of products in various regions across the world including the US, Canada, Australasia, Latin America, and Central and Eastern Europe. The company has manufacturing facilities in Canada, Mexico, the US and countries in Europe, North Africa, Asia and South America. Valeant is headquartered in Laval, Quebec, Canada.

Valeant Pharmaceuticals International Inc (VRX) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Valeant Pharmaceuticals International Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 8
Valeant Pharmaceuticals International Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 9
Valeant Pharmaceuticals International Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 10
Valeant Pharmaceuticals International Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 11
Valeant Pharmaceuticals International Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 12
Valeant Pharmaceuticals International Inc, Medical Equipment, Deal Details 16
Asset Purchase 16
Valeant Pharma to Acquire Rights to IBSchek in US and Canada form Commonwealth Labs 16
Valeant Pharma Acquires Medical Devices And Food Supplements Assets Of Croma-Pharma 17
Valeant Pharma to Acquire Dental Whitening Business from Klox Technologies 18
Venture Financing 19
AcuFocus Raises Funds Through Series F Financing 19
Private Equity 21
Valeant Pharma Rejects Joint Takeover Bid from Takeda Pharma and TPG Capital Management 21
Water Street Healthcare Partners Acquires OraPharma 22
Partnerships 23
Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 23
Namtall Enters into Licensing Agreement with Valeant Pharma 25
Bausch & Lomb Enters Into Licensing Agreement With Cirle 26
Unilens Vision Sciences Amends Licensing Agreement With Bausch & Lomb 27
Bausch & Lomb Enters Into Licensing Agreement With UltraVision 28
Swedish Orphan Biovitrum Enters into Distribution Agreement with PharmaSwiss 29
Synergetics USA Enters Into Agreement With Cleveland Clinic To Develop Next Generation Intraoperative Devices 30
Valeant Pharmaceuticals International Partners With Living Proof 31
Obagi Medical Products Extends Distribution Agreement With Suneva Medical 32
Bausch & Lomb Enters Into Distribution Agreement With PhysIOL For Hydrophilic Acrylic Intraocular Lenses 33
Leica Microsystems Enters Into Distribution Agreement With Bausch & Lomb 34
Obagi Medical Products Enters Into Distribution Agreement With Suneva Medical For ReGenica Facial Rejuvenation Complex 35
Solta Medical Expands Co-Marketing Agreement With SkinCeuticals 36
Bausch & Lomb Enters Into Agreement With Cirle For Medical Technologies 37
Sinclair IS Pharma Enters Into Distribution Agreement With Valeant Pharma For Injectable Dermal Fillers 38
Solta Medical Enters Into Co-Marketing Agreement With SkinCeuticals 39
OrthoScan Enters Into Distribution Agreement With Ziehm Imaging 40
Unilens Vision Enters Into Distribution Agreement With No. 7 Contact Lens Lab 41
Bausch & Lomb Enters Into Distribution Agreement With Technolas Perfect Vision 42
Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 43
Bausch & Lomb Enters Into Licensing Agreement With Paragon BioTeck For Phenylephrine 44
Equity Offering 45
Bausch & Lomb Withdraws IPO 45
Solta Medical Completes Public Offering Of Common Stock For US$17 Million 47
Synergetics USA Files Registration Statement For Public Offering To Raise Up To US$50 Million 48
Debt Offering 49
Valeant Pharma Prices Private Placement of 9% Notes Due 2025 for USD1.18 Billion 49
Valeant Pharma Raises USD591.4 Million in Private Placement of 5.5% Notes Due 2025 50
Valeant Pharma Raises USD801.4 Million in Private Placement of Notes 51
Valeant Pharma Raises USD1.5 Billion in Public Offering of 7% Notes Due 2024 52
Valeant Pharma Raises USD1 Billion in Public Offering of 6.5% Notes Due 2022 53
Solta Medical Completes Private Placement Of Debt Securities For US$40 Million 54
Valeant Pharma Completes Private Placement Of Notes Due 2020 For US$1.75 Billion 55
Valeant Pharma Completes Private Placement Of Notes Due 2020 For US$500 Million 56
Valeant Pharma International Completes Private Placement Of Senior Unsecured Notes Due 2016 For US$950 Million 57
Valeant Pharma International Completes Private Placement Of Senior Unsecured Notes Due 2022 For US$550 Million 59
Valeant Pharma Completes Private Placement Of 6.75% Senior Unsecured Notes Due 2021 For US$650 Million 61
Asset Transactions 62
Valeant Pharma International May Sell Eye Surgery Assets to Carl Zeiss Meditec 62
Valeant Pharma May Sell its Eye-Surgery Equipment Business for up to USD2.5 Billion 63
Almirall Plans to Acquire Dermatology Assets from Valeant Pharmaceuticals 64
Stryker Acquires Neuro Portfolio Assets of Synergetics 65
Galderma Completes Acquisition of Aesthetic Dermatology Assets from Valeant Pharma for USD1.4 Billion 66
Medicis Pharma Plans Sale Of LipoSonix Device 67
Acquisition 68
Valeant Pharma to Sell Sprout Pharma 68
Pershing Square Capital Management Sells its Investment in Valeant Pharma 69
Bausch & Lomb Acquires Doctor’s Allergy Formula 70
Valeant Pharma Acquires Synergetics 71
Valeant Pharma to Acquire Unilens Vision 73
Valeant Canada Acquires CROMA Pharma Canada 74
Valeant Pharma Completes Acquisition Of Solta Medical For US$250 Million 75
Valeant Pharma Completes Acquisition Of Bausch & Lomb For US$ 8.7 Billion 77
Synergetics USA Acquires M.I.S.S. Ophthalmics For US$3 Million 79
OlainFarm Acquires Additional 23.37% Stake In Silvanols, Pharma Products Manufacturer 80
Valeant Pharma Acquires Croma-Pharma Polska And Croma Romania From Croma-Pharma 81
Solta Medical Completes Acquisition Of Sound Surgical For Up To US$40 Million 82
Bausch & Lomb Completes Acquisition Of Remaining Stake In Technolas Perfect Vision From 20/10 Perfect Vision For US$631 Million 83
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 85
Jelfa Acquires Emo-Farm From ICN Polfa Rzeszow For US$10 Million 87
Valeant Pharma Completes Acquisition Of Orapharma From Water Street Healthcare Partners For US$442 Million 88
Bausch & Lomb Acquires Laboratorio Pfortner Cornealent SACIF 90
Solta Medical Acquires Medicis Technologies From Medicis Pharma 91
ATON Acquires 100% Stake In OrthoScan 92
Valeant Pharmaceuticals International Inc – Key Competitors 93
Valeant Pharmaceuticals International Inc – Key Employees 94
Valeant Pharmaceuticals International Inc – Locations And Subsidiaries 95
Head Office 95
Other Locations & Subsidiaries 95
Recent Developments 104
Financial Announcements 104
Nov 07, 2017: Valeant Announces Third-Quarter 2017 Results 104
Aug 08, 2017: Valeant Announces Second-Quarter 2017 Results 106
May 09, 2017: Valeant Announces First Quarter 2017 Results And Raises Full Year Adjusted EBITDA Guidance Range 109
Feb 28, 2017: Valeant Reports Fourth Quarter And Full Year 2016 Financial Results And Provides 2017 Guidance 110
Nov 08, 2016: Valeant Reports Third Quarter 2016 Financial Results 114
Aug 09, 2016: Valeant Pharmaceuticals Reports Second Quarter 2016 Financial Results 117
Jun 07, 2016: Valeant Pharmaceuticals Reports First Quarter 2016 Financial Results 119
Mar 15, 2016: Valeant Pharmaceuticals Reports Preliminary Unaudited Fourth Quarter 2015 Financial Information 121
Corporate Communications 122
Sep 15, 2017: Valeant Commits $200,000 to Support Hurricane Relief Efforts 122
Jun 22, 2017: Bausch + Lomb Named Most Trusted Contact Lens Solution Brand In Canada For Second Consecutive Year By Brandspark International 123
Jun 19, 2017: Valeant Appoints Arthur J. Shannon As Senior Vice President, Head Of Investor Relations And Communications 124
Jun 19, 2017: John Paulson Joins Valeant Board Of Directors 125
May 05, 2017: Valeant Announces Key Appointments In Dermatology And Corporate Communications Leadership 126
Jan 04, 2017: Valeant Pharmaceuticals Announces Addition Of Richard U. DeSchutter To Its Board Of Directors 127
Dec 12, 2016: Valeant Appoints William D. Humphries As EVP, Dermatology 128
Oct 06, 2016: Valeant Appoints Louis W. Yu, Ph.D. As Chief Quality Officer 129
Aug 22, 2016: Valeant Pharmaceuticals Appoints Paul S. Herendeen As Executive Vice President, Finance And Chief Financial Officer 130
Aug 08, 2016: Valeant Pharmaceuticals Announces Changes To Executive Management Team 131
Jul 28, 2016: Valeant Pharmaceuticals Announces The Addition Of Sarah B. Kavanagh To Its Board Of Directors 133
Jun 15, 2016: Valeant Pharmaceuticals Appoints Thomas W. Ross, Sr. Lead Independent Director 134
May 26, 2016: Valeant Pharmaceuticals Names Sam Eldessouky Senior Vice President And Corporate Controller 135
May 03, 2016: Joseph C. Papa Assumes Role Of Chairman And Chief Executive Officer Of Valeant Pharmaceuticals 136
Apr 29, 2016: Valeant Announces Nominees For Election To Board Of Directors 137
Apr 25, 2016: Valeant Names Joseph C. Papa To Be Chairman And Chief Executive Officer Of Valeant Pharmaceuticals 139
Mar 21, 2016: Valeant Announces CEO Succession Plan And Changes To Board Of Directors 140
Mar 09, 2016: Valeant Pharmaceuticals Announces The Addition Of Three New Independent Directors To Its Board 141
Mar 02, 2016: Valeant Pharmaceuticals Announces Management Change 143
Feb 28, 2016: Valeant Pharmaceuticals Announces Management And Business Update 144
Legal and Regulatory 145
Aug 10, 2016: Valeant Pharmaceuticals Comments On SDNY Investigation 145
Mar 09, 2016: Valeant And R&O Pharmacy End Litigation 146
Government and Public Interest 147
Nov 17, 2016: Former Valeant Executive And Former Philidor Ceo Charged In Manhattan Federal Court For Illegal Fraud And Kickback Scheme 147
Product News 149
May 22, 2017: Bausch + Lomb Introduces renu Advanced Formula Multi-Purpose Solution 149
Other Significant Developments 150
Nov 15, 2017: Bausch + Lomb Helps To Recycle More Than One Million Units Of Contact Lens Materials Within First Year Of Launching The ONE By ONE Recycling Program 150
Jun 17, 2016: Valeant Pharmaceuticals Announces Significant Investments In Canadian Operations 151
May 16, 2016: Valeant Pharmaceuticals Provides Update on Regulatory Matters 152
Apr 13, 2016: Valeant Pharmaceuticals Provides Update Regarding Regulatory Matters 153
Mar 21, 2016: Valeant Provides Accounting And Financial Reporting Update 154
Appendix 157
Methodology 157
About GlobalData 157
Contact Us 157
Disclaimer 157

List of Tables
Valeant Pharmaceuticals International Inc, Medical Equipment, Key Facts, 2016 2
Valeant Pharmaceuticals International Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Valeant Pharmaceuticals International Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 8
Valeant Pharmaceuticals International Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 9
Valeant Pharmaceuticals International Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 10
Valeant Pharmaceuticals International Inc, Deals By Market, 2011 to YTD 2017 11
Valeant Pharmaceuticals International Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 12
Valeant Pharma to Acquire Rights to IBSchek in US and Canada form Commonwealth Labs 16
Valeant Pharma Acquires Medical Devices And Food Supplements Assets Of Croma-Pharma 17
Valeant Pharma to Acquire Dental Whitening Business from Klox Technologies 18
AcuFocus Raises Funds Through Series F Financing 19
Valeant Pharma Rejects Joint Takeover Bid from Takeda Pharma and TPG Capital Management 21
Water Street Healthcare Partners Acquires OraPharma 22
Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 23
Namtall Enters into Licensing Agreement with Valeant Pharma 25
Bausch & Lomb Enters Into Licensing Agreement With Cirle 26
Unilens Vision Sciences Amends Licensing Agreement With Bausch & Lomb 27
Bausch & Lomb Enters Into Licensing Agreement With UltraVision 28
Swedish Orphan Biovitrum Enters into Distribution Agreement with PharmaSwiss 29
Synergetics USA Enters Into Agreement With Cleveland Clinic To Develop Next Generation Intraoperative Devices 30
Valeant Pharmaceuticals International Partners With Living Proof 31
Obagi Medical Products Extends Distribution Agreement With Suneva Medical 32
Bausch & Lomb Enters Into Distribution Agreement With PhysIOL For Hydrophilic Acrylic Intraocular Lenses 33
Leica Microsystems Enters Into Distribution Agreement With Bausch & Lomb 34
Obagi Medical Products Enters Into Distribution Agreement With Suneva Medical For ReGenica Facial Rejuvenation Complex 35
Solta Medical Expands Co-Marketing Agreement With SkinCeuticals 36
Bausch & Lomb Enters Into Agreement With Cirle For Medical Technologies 37
Sinclair IS Pharma Enters Into Distribution Agreement With Valeant Pharma For Injectable Dermal Fillers 38
Solta Medical Enters Into Co-Marketing Agreement With SkinCeuticals 39
OrthoScan Enters Into Distribution Agreement With Ziehm Imaging 40
Unilens Vision Enters Into Distribution Agreement With No. 7 Contact Lens Lab 41
Bausch & Lomb Enters Into Distribution Agreement With Technolas Perfect Vision 42
Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 43
Bausch & Lomb Enters Into Licensing Agreement With Paragon BioTeck For Phenylephrine 44
Bausch & Lomb Withdraws IPO 45
Solta Medical Completes Public Offering Of Common Stock For US$17 Million 47
Synergetics USA Files Registration Statement For Public Offering To Raise Up To US$50 Million 48
Valeant Pharma Prices Private Placement of 9% Notes Due 2025 for USD1.18 Billion 49
Valeant Pharma Raises USD591.4 Million in Private Placement of 5.5% Notes Due 2025 50
Valeant Pharma Raises USD801.4 Million in Private Placement of Notes 51
Valeant Pharma Raises USD1.5 Billion in Public Offering of 7% Notes Due 2024 52
Valeant Pharma Raises USD1 Billion in Public Offering of 6.5% Notes Due 2022 53
Solta Medical Completes Private Placement Of Debt Securities For US$40 Million 54
Valeant Pharma Completes Private Placement Of Notes Due 2020 For US$1.75 Billion 55
Valeant Pharma Completes Private Placement Of Notes Due 2020 For US$500 Million 56
Valeant Pharma International Completes Private Placement Of Senior Unsecured Notes Due 2016 For US$950 Million 57
Valeant Pharma International Completes Private Placement Of Senior Unsecured Notes Due 2022 For US$550 Million 59
Valeant Pharma Completes Private Placement Of 6.75% Senior Unsecured Notes Due 2021 For US$650 Million 61
Valeant Pharma International May Sell Eye Surgery Assets to Carl Zeiss Meditec 62
Valeant Pharma May Sell its Eye-Surgery Equipment Business for up to USD2.5 Billion 63
Almirall Plans to Acquire Dermatology Assets from Valeant Pharmaceuticals 64
Stryker Acquires Neuro Portfolio Assets of Synergetics 65
Galderma Completes Acquisition of Aesthetic Dermatology Assets from Valeant Pharma for USD1.4 Billion 66
Medicis Pharma Plans Sale Of LipoSonix Device 67
Valeant Pharma to Sell Sprout Pharma 68
Pershing Square Capital Management Sells its Investment in Valeant Pharma 69
Bausch & Lomb Acquires Doctor’s Allergy Formula 70
Valeant Pharma Acquires Synergetics 71
Valeant Pharma to Acquire Unilens Vision 73
Valeant Canada Acquires CROMA Pharma Canada 74
Valeant Pharma Completes Acquisition Of Solta Medical For US$250 Million 75
Valeant Pharma Completes Acquisition Of Bausch & Lomb For US$ 8.7 Billion 77
Synergetics USA Acquires M.I.S.S. Ophthalmics For US$3 Million 79
OlainFarm Acquires Additional 23.37% Stake In Silvanols, Pharma Products Manufacturer 80
Valeant Pharma Acquires Croma-Pharma Polska And Croma Romania From Croma-Pharma 81
Solta Medical Completes Acquisition Of Sound Surgical For Up To US$40 Million 82
Bausch & Lomb Completes Acquisition Of Remaining Stake In Technolas Perfect Vision From 20/10 Perfect Vision For US$631 Million 83
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 85
Jelfa Acquires Emo-Farm From ICN Polfa Rzeszow For US$10 Million 87
Valeant Pharma Completes Acquisition Of Orapharma From Water Street Healthcare Partners For US$442 Million 88
Bausch & Lomb Acquires Laboratorio Pfortner Cornealent SACIF 90
Solta Medical Acquires Medicis Technologies From Medicis Pharma 91
ATON Acquires 100% Stake In OrthoScan 92
Valeant Pharmaceuticals International Inc, Key Competitors 93
Valeant Pharmaceuticals International Inc, Key Employees 94
Valeant Pharmaceuticals International Inc, Other Locations 95
Valeant Pharmaceuticals International Inc, Subsidiaries 95

★海外企業調査レポート[Valeant Pharmaceuticals International Inc (VRX)-医療機器分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • ChemoCentryx Inc (CCXI)：企業の財務・戦略的SWOT分析
    Summary ChemoCentryx Inc (ChemoCentryx) is a biopharmaceutical company that discovers, develops and commercializes orally-administered therapeutics for the treatment of cancer, autoimmune diseases, and inflammatory disorders. The company's lead drug candidate include Avacopan, an orally-administered …
  • TherOx Inc：医療機器：M&Aディール及び事業提携情報
    Summary TherOx Inc (TherOx) is a medical device company that develops and commercializes SuperSaturated Oxygen (SSO2) therapies for treatment of heart attack. Its SSO2 therapy is designed to ameliorate progressive myocardial necrosis by minimizing microvascular damage in heart attack patients. TherO …
  • Gindalbie Metals Ltd：企業の戦略・SWOT・財務情報
    Gindalbie Metals Ltd - Strategy, SWOT and Corporate Finance Report Summary Gindalbie Metals Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Lyka Labs Ltd (LYKALABS)-製薬・医療分野：企業M&A・提携分析
    Summary Lyka Labs Ltd (Lyka Labs) is a developer and manufacturer of pharmaceutical formulations and active pharmaceutical ingredients. The company offers development of various formulations which include lyophilized injections, differentiated dermatological formulation, dry powder injections, and o …
  • Analog Devices, Inc.：戦略・SWOT・企業財務分析
    Analog Devices, Inc. - Strategy, SWOT and Corporate Finance Report Summary Analog Devices, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Charoen Pokphand Foods Public Company Limited：企業の戦略・SWOT・財務情報
    Charoen Pokphand Foods Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary Charoen Pokphand Foods Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, opera …
  • I.Ceram SA (ALICR)：医療機器：M&Aディール及び事業提携情報
    Summary I.Ceram SA (I.Ceram) is a medical equipment and device company that designs, manufactures, and markets joint implants for neurosurgery and other surgical procedures. The company’s products include bone fillers, alumina bio-ceramic implants, trepan caps, cervical plates and blocks for cervica …
  • KP Energy Ltd (539686)：電力：M&Aディール及び事業提携情報
    Summary KP Energy Ltd (KP Energy) is an alternative energy company that offers power and wind energy solutions. The company provides services such as turnkey solutions, BOT basis services, land acquisition, project development, cost studies, site identification, capacity installations, engineer, pro …
  • Scorpio Tankers Inc. (STNG)：企業の財務・戦略的SWOT分析
    Scorpio Tankers Inc. (STNG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Mekonomen AB：企業の戦略・SWOT・財務情報
    Mekonomen AB - Strategy, SWOT and Corporate Finance Report Summary Mekonomen AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Jardine Cycle & Carriage Ltd (C07)：企業の財務・戦略的SWOT分析
    Jardine Cycle & Carriage Ltd (C07) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • PQ Group Holdings Inc (PQG)：企業の財務・戦略的SWOT分析
    PQ Group Holdings Inc (PQG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • UMW Holdings Bhd (UMW)：石油・ガス：M&Aディール及び事業提携情報
    Summary UMW Holdings Bhd (UMW) is a diversified company. The company operates through its business divisions such as automotive, equipment, manufacturing and engineering, and oil and gas. Its automotive business manufactures, assembles, markets and distributes passenger cars and commercial vehicles. …
  • Catholic Health Initiatives：企業のM&A・事業提携・投資動向
    Catholic Health Initiatives - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Catholic Health Initiatives Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Boehringer Ingelheim GmbH-医療機器分野：企業M&A・提携分析
    Summary Boehringer Ingelheim GmbH (Boehringer), a subsidiary of C. H. Boehringer Sohn AG & Co KG is a pharmaceutical company, which carries out research, development, manufacture and sale of pharmaceuticals. The company offers a wide range of products including prescription medicines, consumer healt …
  • Molecular Partners AG (MOLN)：企業の財務・戦略的SWOT分析
    Summary Molecular Partners AG (Molecular Partners) is a clinical stage bio pharmaceutical company that develops biological drugs. The company offers advanced small protein therapies such as abicipar, a designed ankyrin repeat protein based anti-angiogenic drug developed for diabetic macular edema an …
  • HomeServe plc (HSV)：企業の財務・戦略的SWOT分析
    HomeServe plc (HSV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • New Carolin Gold Corp：企業の戦略・SWOT・財務情報
    New Carolin Gold Corp - Strategy, SWOT and Corporate Finance Report Summary New Carolin Gold Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • freenet AG：企業のM&A・事業提携・投資動向
    freenet AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's freenet AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • SK Chemicals Co Ltd (006120)：製薬・医療：M&Aディール及び事業提携情報
    Summary SK Chemicals Co Ltd (SK Chemicals) is a chemical company that provides life sciences products and solutions. The company manufactures polyester and acetate yarns for textile, and industrial uses. Its copolyesters comprise ecozen, skygreen and skypets. SK Chemicals provides high-performance r …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆